Clinical Trial Centre

Clinical Trial Centre

Clinical Trial Centre

The Clinical Trial Centre has been established with the primary objective of conducting high-quality clinical research to support the development of new drugs on 11 October 2022. This initiative aims to contribute significantly to medical advancements by ensuring the safety and efficacy of new treatments before they reach the market. The inauguration ceremony was marked by a formal ribbon-cutting and Nariyal Fodne ritual, symbolizing new beginnings and success. The event was graced by the Honourable Vice Chancellor of SRHU, Dr Vijay Dhasmana, along with Dr Rajendra Dobhal, Director, Strategies Planning, Research & Development, SRHU, emphasizing the institution’s commitment to fostering research excellence in clinical trials. Clinical trials in India involve systematic testing of new drugs, therapies, and medical interventions on human participants to evaluate their safety, efficacy, and potential side effects. These trials are conducted under strict regulatory frameworks, including the New Drugs and Clinical Trials Rules (NDCTR) 2019, Indian Council of Medical Research (ICMR) Guidelines, and Drugs Controller General of India (DCGI) regulations. As per government mandates, all clinical trials must be registered in the Clinical Trials Registry - India (CTRI) before initiation, ensuring transparency and adherence to ethical research standards. Dr Nikku Yadav assured that all clinical trials conducted at the center will strictly comply with national and international regulatory requirements. No study will proceed without obtaining necessary approvals from DCGI and oversight from an independent Institutional Ethics Committee (IEC) to uphold ethical standards. To enhance the efficiency of clinical trial operations, the center has partnered with Somaya Research and Health Services (SRHS) LLP, a distinguished Site Management Organization (SMO), as well as KV Clinical Research, Chhattisgarh, to expand research capabilities and ensure streamlined operations. These partnerships will facilitate patient recruitment, regulatory compliance, and data management while strengthening multi-center clinical trials across different locations. The center will conduct clinical trials for multiple therapeutic indications, including cardiovascular diseases, metabolic disorders such as diabetes and PCOS, neurological disorders like Alzheimer’s and epilepsy, infectious diseases, oncology, and rare/orphan diseases. Our team of experienced clinicians and researchers will actively contribute to drug development, bringing new treatments closer to clinical application.

A key focus of the center is to provide hands-on training to students enrolled in the Clinical Research program, equipping them with practical experience in clinical trial management. Under expert supervision, students will be trained in protocol development, regulatory submissions, patient recruitment, informed consent processes, data collection, monitoring, adverse event reporting, and pharmacovigilance. This real-world exposure will enhance their skills and prepare them for careers in the pharmaceutical, biotechnology, and healthcare industries.

Before initiating any clinical trial, the center will obtain approvals from DCGI, IEC, and other regulatory authorities to ensure compliance with ethical guidelines. Patient rights, confidentiality, and informed consent will be strictly upheld throughout the research process. The establishment of this clinical trial center marks a significant step in advancing medical research and drug development in India. Through regulatory compliance, collaboration, and a commitment to ethical research, the center aims to contribute to the discovery of innovative treatments that improve patient care. Furthermore, by integrating research with education, the center will provide invaluable training opportunities for students, strengthening the future workforce in clinical research.

Functional Areas of Clinical Trial Centre

Ensuring regulatory compliance, ethical standards, and data integrity.

Clinical Trial Operations
Data Management & Biostatistics
Quality Assurance & Auditing

List of Regulatory Trials Completed/Ongoing/ Under-pipeline

Sr. No. Indication Sponsor CRO Study Start Date Trial Status Patient Recruited Monitoring Visits
1 Metastatic Non-small Cell lung cancer Zydus Life Sciences, Ahmadabad, GJ Cliantha Research, Mumbai, MH 09/Mar/2023 to 10/Mar/2023 Close out 4 08/Nov/2023, 09-10/Mar/2023, 30-31/May/2023, 28-29/Jun/2023, 05-06/Sep/2023, 16-17/Oct/2023, 29-30/Nov/2023, 11-12/Apr/2024
2 Rheumatoid arthritis Virchow Biotech Pvt. Ltd. Hyderabad, Telangana NMC Clinical Services, Hyderabad, Telangana 14/Jul/2023 Close out 3 14/Jul/2023, 03/Apr/2024
3 Multiple Myeloma Pfizer Ltd Mumbai, MH Parexel India, Mumbai, MH 06/Jun/2023 to 07/Jun/2023 Ongoing 2 03/Jan/2023, 06-07/Jun/2023, 28-29/Sep/2023, 26/Oct/2023, 19-20/Dec/2023, 16/Feb/2024, 12-13/Mar/2024, 29-30/Apr/2024, 13-14/Jun/2024, 19-20/Feb/2025
4 Established Cardiovascular Disease Novartis Ltd, Mumbai, MH 08/Jun/2023 to 09/Jun/2023 Ongoing 8 08-09/Jun/2023, 10-11/Jul/2023, 19-20/Oct/2023, 09-10/Jan/2024, 04-05/Apr/2024, 06/Jun/2024, 9-10/Jan/2025
5 Atherosclerotic Cardiovascular Disease Novartis Ltd, Mumbai, MH 20/Jul/2023 to 21/Jul/2023 Ongoing 13 20-21/Jul/2023, 08/Sep/2023, 04-06/Dec/2023, 06-08/Mar/2024, 05-06/Jun/2024
6 HER 2 + Breast Cancer Hetero Biopharma Ltd, Hyderabad, Telangana Insignia Clinical Services Pvt. Ltd, New Delhi 03/May/2024 Closed - Operational irregularly
7 Invasive Fungal Infection Gufic Biosciences Limited, Mumbai, MH - 15/Mar/2024 Closed - Operational irregularly
8 Chronic Hyperuricemia Vivotech Research Lab Pvt. Ltd, Mumbai, MH - - Closed - Operational irregularly
9 Lung Cancer Tecentriq® Lung Registry Roche India, New Delhi Eversana Ltd, Mumbai, MH - Dossier submitted to EC - Ethical Issues
10 ER+/HER-Early Breast Cancer Astrazeneca Ltd, Bangalore, KA - - CTA - Operational irregularly
11 HER 2- Negative Breast Cancer Astrazeneca Ltd, Bangalore, KA - 21/Feb/2025 CTA - Ongoing
12 Wet Age-Related Macular Degeneration (PROMISES Study) Gennova Biopharmaceuticals Limited CRNI - CTA - Under pipeline
13 Semaglutide Injection in Comparison with Reference Biologic in Obesity Management Zydus Lifesciences Limited - - Dossier submitted to EC - Under pipeline
14 Newly Diagnosed Multiple Myeloma Lambda Therapeutic Research Limited - - Feasibility done - Under pipeline

Contact Us

Dr Nikku Yadav

Head, Department of Clinical Research,
HIMS CRI Building Basement, Himalayan Hospital


Hod.cr@srhu.edu.in
O1352471588, O1352471545

   Admissions Form         

Admission Open For 2025

×
International Endowed Chair Professor

Prof Rakesh Kumar

Prof Rakesh Kumar is the Founder and President of the Breast Cancer in Young Women Foundation (USA), dedicated to vaddressing the distinct issues affecting young women with breast cancer. He also serves as the International Endowed Chair Professor at the Cancer Research Institute of the Himalayan Institute of Medical Sciences. Additionally, he holds adjunct professorships at Rutgers New Jersey Medical School and Virginia Commonwealth University.

Dr Kumar earned his Ph.D. from the All India Institute of Medical Sciences in 1984 and began his research career at Memorial Sloan Kettering Cancer Center in January 1986. From 1988 to 2017, he held various academic and leadership positions —including faculty member, tenured professor, distinguished professor, endowed chair, department chair, and research leader—at esteemed institutions such as Memorial Sloan Kettering Cancer Center in New York and the University of Texas MD Anderson Cancer Center in Houston. From 2017 to 2022, he served as the National Chair for Cancer Research for the Government of India and as a distinguished professor, continuing his innovative work in breast cancer research.

With nearly 40 years of research and professional experience, Dr. Kumar has made conceptual contributions to the field of cancer research (h-index 108, citations >50,000). He has authored over 325 peer-reviewed publications, edited or co-edited nine books, and delivered 290 invited lectures worldwide. His work has been featured on the covers of 18 major cancer journals and has been highlighted in institutional research reports of the MD Anderson Cancer Center.

A passionate educator and mentor, Dr. Kumar has guided 67 trainees throughout his career. He serves on the editorial boards of multiple leading cancer journals and has served on the editorial boards of 21 top cancer journals. His global reputation is further demonstrated by his participation in about 100 peer-review panels for cancer research funding in the US and internationally over the past 28 years.

Dr. Kumar's innovative research has earned him numerous prestigious honors, including the Hinkle Society Faculty Award at Penn State University (1994), the Dalla/Fort Worth Living Legend Faculty Achievement Award in Basic Sciences (2004), the Ranbaxy Research Award (2006), and the Lifetime Achievement Award from the American Association of Indian Scientists in Cancer Research (2013), among others. Dr. Kumar's pioneering research continues to have a profound influence on the fields of oncology and breast cancer, opening up new opportunities for biomedical scientists and trainees worldwide.